Growth Metrics

Bio-Techne (TECH) EBITDA Margin (2009 - 2026)

Bio-Techne's quarterly EBITDA Margin came in at 14.94% in Q1 2026, up 666.0% year-on-year from 1.95% in Q1 2025, and up 10.37% quarter-over-quarter from 13.54% in Q4 2025.

Bio-Techne has reported EBITDA Margin for 18 years, with the latest figure at 14.94% in Q1 2026.

  • For the quarter ending Q1 2026, EBITDA Margin rose 666.0% year-over-year to 14.94%; the trailing twelve-month figure through Mar 2026 stood at 10.3% (down 3.0% YoY), and the FY2025 full-year result was 7.53%, down 592.0% from the prior year.
  • EBITDA Margin for Q1 2026 stood at 14.94%, up from 13.54% in the prior quarter.
  • The five-year high for EBITDA Margin was 3647.25% in Q3 2022, with the low at 1.42% in Q2 2025.
  • Average EBITDA Margin over 5 years is 228.56%, with a median of 14.39% recorded in 2022.
  • Year-over-year, EBITDA Margin soared 362293 bps in 2022 and tumbled 363315 bps in 2023.
  • Tracing TECH's EBITDA Margin over 5 years: stood at 24.56% in 2022, then slumped by 38 bps to 15.34% in 2023, then tumbled by 80 bps to 3.14% in 2024, then jumped by 331 bps to 13.54% in 2025, then rose by 10 bps to 14.94% in 2026.
  • The last three EBITDA Margin figures came in at 14.94% (Q1 2026), 13.54% (Q4 2025), and 11.75% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 18.35%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.24%
10 Bio-Techne 7.92 Bn 7.71 Bn 208.29 Mn 14.94%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 14.94%
Dec 31, 2025 13.54%
Sep 30, 2025 11.75%
Jun 30, 2025 1.42%
Mar 31, 2025 8.28%
Dec 31, 2024 3.14%
Sep 30, 2024 17.91%
Jun 30, 2024 12.28%
Mar 31, 2024 12.33%
Dec 31, 2023 15.34%
Sep 30, 2023 14.10%
Jun 30, 2023 27.54%
Mar 31, 2023 24.41%
Dec 31, 2022 24.56%
Sep 30, 2022 3,647.25%
Jun 30, 2022 14.39%
Mar 31, 2022 22.41%
Dec 31, 2021 31.53%
Sep 30, 2021 24.32%
Jun 30, 2021 8.37%
Mar 31, 2021 18.89%
Dec 31, 2020 29.06%
Sep 30, 2020 23.24%
Jun 30, 2020 37.03%
Mar 31, 2020 5.82%
Dec 31, 2019 71.86%
Sep 30, 2019 3.43%
Jun 30, 2019 6.56%
Mar 31, 2019 25.98%
Dec 31, 2018 2.97%
Sep 30, 2018 9.98%
Jun 30, 2018 7.07%
Mar 31, 2018 37.01%
Dec 31, 2017 27.11%
Sep 30, 2017 10.40%
Jun 30, 2017 28.08%
Mar 31, 2017 16.73%
Dec 31, 2016 3.17%
Sep 30, 2016 19.39%
Jun 30, 2016 23.51%
Mar 31, 2016 4.08%
Dec 31, 2015 23.11%
Sep 30, 2015 -0.28%
Jun 30, 2015 31.75%
Mar 31, 2015 6.26%
Dec 31, 2014 28.33%
Sep 30, 2014 5.82%
Jun 30, 2014 27.39%
Mar 31, 2014 39.44%
Dec 31, 2013 35.02%
Sep 30, 2013 -1.69%
Jun 30, 2013 37.91%
Mar 31, 2013 44.08%
Dec 31, 2012 31.26%
Sep 30, 2012 21.37%
Jun 30, 2012 53.56%
Mar 31, 2012 71.20%
Dec 31, 2011 33.66%
Sep 30, 2011 30.40%
Jun 30, 2011 54.59%
Mar 31, 2011 58.66%
Dec 31, 2010 55.16%
Sep 30, 2010 56.46%
Jun 30, 2010 -93.90%
Mar 31, 2010 59.26%
Dec 31, 2009 55.79%
Sep 30, 2009 58.92%